Publication Name	World Journal of Hepatology
Manuscript ID	33807
Country	France

Received	2017-03-05 17:38
Peer-Review Started	2017-03-07 16:35
To Make the First Decision	2017-03-27 11:28
Return for Revision	2017-03-28 16:14
Revised	2017-04-01 02:22
Second Decision	2017-04-14 11:32
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2017-04-24 10:17
Articles in Press	2017-04-24 10:17
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2017-05-03 17:25
Publish the Manuscript Online	2017-05-08 11:13

ISSN	1948-5182 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Review
Article Title	Hepatic complications induced by immunosuppressants and biologics in inflammatory bowel disease
Manuscript Source	Invited Manuscript
All Author List	My-Linh Tran-Minh, Paula Sousa, Marianne Maillet, Matthieu Allez and Jean-Marc Gornet
Funding Agency and Grant Number
Corresponding Author	Dr. Jean-Marc Gornet, Department of Gastroenterology, AP-HP, Saint Louis Hospital, 1 Avenue Claude Vellefaux, 75010 Paris, France. jean-marc.gornet@aphp.fr
Key Words	Drug induced liver toxicity; Inflammatory bowel disease; Crohn’s disease; Ulcerative colitis
Core Tip	The therapeutic options for inflammatory bowel disease (IBD) are expanding, and the number of drugs will rapidly increase in coming years. The fear of side effects represents one the most limiting factor of their use. Despite a widespread use for years, drug induced liver injury (DILI) management remains a challenging situation with Azathioprine and Methotrexate. DILI seems less frequent with anti-tumor necrosis factor agents and new biologic therapies. The aim of this review is to report incidence, physiopathology and practical guidelines in case of DILI occurrence with the armamentarium of old and new drugs in the field of IBD.
Publish Date	2017-05-08 11:13
Citation	Tran-Minh ML, Sousa P, Maillet M, Allez M, Gornet JM. Hepatic complications induced by immunosuppressants and biologics in inflammatory bowel disease. World J Hepatol 2017; 9(13): 613-626
URL	http://www.wjgnet.com/1948-5182/full/v9/i13/613.htm
DOI	http://dx.doi.org/10.4254/wjh.v9.i13.613

Full Article (PDF)	WJH-9-613.pdf
Full Article (Word)	WJH-9-613.doc
Manuscript File	33807-Review.docx
Answering Reviewers	33807-Answering reviewers.pdf
Audio Core Tip	33807-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	33807-Conflict-of-interest statement.pdf
Copyright License Agreement	33807-Copyright assignment.pdf
Peer-review Report	33807-Peer-review(s).pdf
Scientific Misconduct Check	33807-Scientific misconduct check.pdf
Scientific Editor Work List	33807-Scientific editor work list.pdf